Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Inc (VRTX) is a global biopharmaceutical leader focused on transformative therapies for serious diseases. This page serves as the definitive source for all official Vertex news, including regulatory milestones, clinical developments, and strategic partnerships.
Investors and researchers will find timely updates on cystic fibrosis treatment advancements, gene-editing therapy progress, and pipeline expansions into pain management and blood disorders. Our curated feed includes earnings announcements, FDA submissions, and peer-reviewed research publications.
The repository features three core categories: Treatment Approvals (new drug applications and label expansions), Research Breakthroughs (clinical trial results and preclinical discoveries), and Strategic Developments (collaborations and manufacturing updates). Each entry provides direct access to primary source materials.
For ongoing monitoring of Vertex's innovations in small-molecule drugs and CRISPR-based therapies, bookmark this page or check back regularly. All content is vetted against original company disclosures to ensure regulatory compliance and factual accuracy.
Vertex Pharmaceuticals (VRTX) received a positive opinion from the European Medicines Agency's CHMP for expanding the label of KAFTRIO® in combination with ivacaftor. The expansion would cover the treatment of cystic fibrosis (CF) patients aged 2 years and older who have at least one non-class I mutation in the CFTR gene.
If approved, this expansion would make approximately 4,000 additional patients in the European Union eligible for CFTR modulator treatment that addresses the underlying cause of their disease. Currently, KAFTRIO is approved in the EU for CF patients aged 2 years and older with at least one copy of the F508del mutation in the CFTR gene.
Vertex Pharmaceuticals (VRTX) has announced its participation in three major investor conferences in March 2025. Stuart Arbuckle, EVP and COO, and David Altshuler, EVP of Global Research and CSO, will join a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3 at 3:10 p.m. ET.
Charles Wagner, EVP and CFO, along with Dr. Altshuler, will participate in the 2025 Leerink Partners Global Healthcare Conference on March 10 at 10:00 a.m. ET. Additionally, Susie Lisa, SVP of Investor Relations, and Miroslava Minkova, Executive Director of IR, will attend the Jefferies Biotech on the Beach Summit on March 11.
Live webcasts of management presentations will be accessible through the company's website at www.vrtx.com under the Investors section, with replays available afterward.
Vertex Pharmaceuticals reported strong financial results for Q4 and full year 2024, with full-year product revenue reaching $11.02 billion, a 12% increase from 2023. The company provided 2025 revenue guidance of $11.75 to $12.0 billion.
Key highlights include FDA approvals for ALYFTREK for cystic fibrosis patients ages 6+ and JOURNAVX for moderate-to-severe acute pain. Q4 2024 product revenue increased 16% to $2.91 billion, with U.S. revenue up 17% to $1.84 billion and international revenue up 14% to $1.07 billion.
The company announced leadership changes, with COO Stuart Arbuckle retiring July 1, 2025. CFO Charlie Wagner will assume the additional role of COO, while Duncan McKechnie will become CCO. Cash position stood at $11.2 billion as of December 31, 2024, down from $13.7 billion year-over-year due to the Alpine acquisition and share repurchases.
Vertex Pharmaceuticals (VRTX) has secured a reimbursement agreement with NHS England for CASGEVY®, its CRISPR/Cas9 gene-edited therapy, for eligible sickle cell disease (SCD) patients. This follows the National Institute for Health and Care Excellence (NICE) issuing positive guidance recommending CASGEVY's use in the NHS.
The agreement expands upon a previous reimbursement deal reached in August 2024 for transfusion-dependent beta thalassemia (TDT) patients. Vertex is working to establish a network of independently operated authorized treatment centers (ATCs) throughout England, as the therapy requires specialized experience in stem cell transplantation and hemoglobinopathy management.
Vertex Pharmaceuticals (NASDAQ: VRTX) has received FDA approval for JOURNAVX™ (suzetrigine), marking a significant breakthrough in pain management. The drug is the first non-opioid oral pain signal inhibitor and the first new pain medicine class approved in over 20 years.
JOURNAVX is specifically designed for treating adults with moderate-to-severe acute pain. As a highly selective NaV1.8 pain signal inhibitor, it offers effective pain relief with a favorable safety profile and no evidence of addictive potential. This development is particularly significant for the approximately 80 million Americans who receive prescriptions for moderate-to-severe acute pain annually.
The company has established patient support programs to facilitate access to JOURNAVX for qualified patients, with more information available at JOURNAVX.com.
Vertex Pharmaceuticals (Nasdaq: VRTX) has scheduled its fourth quarter and full year 2024 financial results announcement for Monday, February 10, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET.
Investors can access the call via phone at (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International), referencing the "Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call". A live webcast will be available through the Investors section of Vertex's website. Participants are advised to register 15 minutes before the scheduled webcast. An archived version will be available on the company's website.
Vertex Pharmaceuticals (NASDAQ: VRTX) announced significant updates ahead of January 2025 investor meetings. The company reported major achievements in 2024, including FDA approval of ALYFTREK for cystic fibrosis treatment and expanded approval for TRIKAFTA. Vertex has activated over 50 authorized treatment centers globally for CASGEVY, with more than 50 patients initiating cell collection.
Key pipeline updates include: awaiting FDA decision for suzetrigine in acute pain (PDUFA date: January 30, 2025), continuing Phase 3 trials for povetacicept in IgA nephropathy, advancing inaxaplin for APOL1-mediated kidney disease, and initiating Phase 3 studies for zimislecel in Type 1 diabetes. The company increased its estimate of CF patients from 92,000 to 94,000 in key markets and identified approximately 15,000 additional patients in new markets.
Vertex secured a unique outcomes-based arrangement with CMS for CASGEVY and received approval in the UAE for both SCD and TDT treatments. The company continues to expand its geographic footprint and diversify its revenue streams through multiple product launches.
Vertex Pharmaceuticals (VRTX) and Zai Lab (ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist being studied for Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases.
Under the agreement, Vertex will receive an upfront payment, regulatory milestone payments, and tiered royalties on net sales. Zai Lab will leverage its R&D expertise to advance clinical trials and handle regulatory submissions in the licensed territory. Once approved, Zai Lab will be responsible for all commercialization activities in the region, utilizing its established commercial infrastructure.
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) have announced an exclusive collaboration and license agreement for the development and commercialization of povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore.
Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL with best-in-class potential, being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases.
Under the agreement terms, Vertex will receive an upfront payment, regulatory milestone payments, and tiered royalties on net sales. Zai Lab will leverage its R&D expertise for clinical trials and regulatory submissions, while also managing all commercialization activities in the licensed territory upon approval.
Orna Therapeutics has announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to develop next-generation gene editing therapies for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). The partnership will utilize Orna's proprietary lipid nanoparticle (LNP) delivery solutions to enhance Vertex's therapeutic development efforts.
Under the agreement, Orna will receive an upfront payment and is eligible for potential pre-clinical, clinical, and commercialization milestone payments, along with royalties. The collaboration aims to leverage Orna's extra-hepatic LNP delivery chemistries to achieve unprecedented delivery to hematopoietic stem cells (HSCs). This marks Orna's second major partnership, highlighting the company's leadership in next-generation RNA medicines.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
